Small Molecules

19 Dec 2017 Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study
19 Dec 2017 Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo
19 Dec 2017 INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric Patients
19 Dec 2017 Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
18 Dec 2017 Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer
18 Dec 2017 SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
18 Dec 2017 Samumed Doses First Patient in Phase 1 Trial of SM04690 for Treatment of Degenerative Disc Disease
18 Dec 2017 Allergan and Richter Announce Positive Topline Results from Phase 3 Study of Cariprazine for the Treatment of Bipolar I Depression
18 Dec 2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial
18 Dec 2017 US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
15 Dec 2017 Pfizer Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the Treatment of Active Psoriatic Arthritis
15 Dec 2017 Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries
14 Dec 2017 Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis
14 Dec 2017 Jenrin Discovery’s IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials
14 Dec 2017 Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
14 Dec 2017 Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers
14 Dec 2017 Principia Biopharma Initiates Clinical Trial for PRN1008 in Patients With Immune Thrombocytopenia Purpura
13 Dec 2017 Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer
13 Dec 2017 Once-Daily, Oral LIXIANA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
12 Dec 2017 AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
12 Dec 2017 Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase 2 Clinical Studies
12 Dec 2017 Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in Combination with Intensive Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia
12 Dec 2017 Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis
12 Dec 2017 Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838
12 Dec 2017 Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top